NCT07007910View on ClinicalTrials.gov

Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
m CRPC
Interventions
DRUG

HSK46575

co-administered with glucocorticoid and fludrocortisone, orally daily

Trial Locations (1)

610044

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT07007910 - Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter